Company Description
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming.
It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues.
The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies.
Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University.
The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021.
Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
| Country | United States |
| IPO Date | Jun 30, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 47 |
| CEO | Amro A. Albanna |
Contact Details
Address: 737 North Fifth Street Richmond, Virginia United States | |
| Website | https://www.aditxt.com |
Stock Details
| Ticker Symbol | ADTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001726711 |
| CUSIP Number | 007025109 |
| ISIN Number | US0070256047 |
| Employer ID | 82-3204328 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Amro A. Albanna | Co-Founder, Chairman & Chief Executive Officer |
| Rowena Albanna | Chief Operating Officer |
| Thomas J. Farley CPA | Chief Financial Officer |
| Corinne D. Pankovcin CPA, M.B.A. | Chief Mergers & Acquisitions Officer |
| Dr. Dolly B. Tyan D(ABHI), Ph.D. | Senior Vice President of Clinical Development Transplantation |
| Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D. | Co-Founder, Chief Innovation Officer, Secretary & Director |
| Ge Chen M.D., M.S. | Senior Vice President of Preclinical Research & Discovery |
| Jennifer Lee | Director of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 12, 2024 | 8-K | Current Report |
| Dec 06, 2024 | PRE 14A | Filing |
| Nov 21, 2024 | 8-K/A | [Amend] Current Report |
| Nov 21, 2024 | 8-K/A | [Amend] Current Report |
| Nov 19, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 10-Q | Quarterly Report |
| Nov 15, 2024 | NT 10-Q | Filing |
| Nov 05, 2024 | 8-K | Current Report |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 8-K | Current Report |